These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33200963)

  • 1. "Profoundly Saddened" Lysogene Discloses Child's Death in Phase II/III Trial.
    Philippidis A
    Hum Gene Ther; 2020 Nov; 31(21-22):1141-1143. PubMed ID: 33200963
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Marcó S; Haurigot V; Bosch F
    Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
    Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
    Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
    Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
    Meadows AS; Duncan FJ; Camboni M; Waligura K; Montgomery C; Zaraspe K; Naughton BJ; Bremer WG; Shilling C; Walker CM; Bolon B; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):228-42. PubMed ID: 26684447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
    Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
    Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. After Third Death, Audentes' AT132 Remains on Clinical Hold.
    Philippidis A
    Hum Gene Ther; 2020 Sep; 31(17-18):908-910. PubMed ID: 32945722
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials. Gene transfer an unlikely contributor to patient's death.
    Kaiser J
    Science; 2007 Dec; 318(5856):1535. PubMed ID: 18063761
    [No Abstract]   [Full Text] [Related]  

  • 9. A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.
    Winner LK; Beard H; Hassiotis S; Lau AA; Luck AJ; Hopwood JJ; Hemsley KM
    Hum Gene Ther; 2016 May; 27(5):363-75. PubMed ID: 26975339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.
    Fu H; Samulski RJ; McCown TJ; Picornell YJ; Fletcher D; Muenzer J
    Mol Ther; 2002 Jan; 5(1):42-9. PubMed ID: 11786044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.
    Ruzo A; Marcó S; García M; Villacampa P; Ribera A; Ayuso E; Maggioni L; Mingozzi F; Haurigot V; Bosch F
    Hum Gene Ther; 2012 Dec; 23(12):1237-46. PubMed ID: 22909060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.
    Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F
    Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hopes, Promises, and Future Directions of Gene and Cell Therapies in France.
    Cartier N; Cordelier P
    Hum Gene Ther; 2016 Feb; 27(2):96-7. PubMed ID: 26886830
    [No Abstract]   [Full Text] [Related]  

  • 14. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
    Ribera A; Haurigot V; Garcia M; Marcó S; Motas S; Villacampa P; Maggioni L; León X; Molas M; Sánchez V; Muñoz S; Leborgne C; Moll X; Pumarola M; Mingozzi F; Ruberte J; Añor S; Bosch F
    Hum Mol Genet; 2015 Apr; 24(7):2078-95. PubMed ID: 25524704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosafety of recombinant adeno-associated virus vectors.
    Dismuke DJ; Tenenbaum L; Samulski RJ
    Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
    O'Connor CM; Gattis WA; Ryan TJ
    Am Heart J; 2000 Apr; 139(4):S143-54. PubMed ID: 10740121
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
    Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
    J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.
    Tardieu M; Zérah M; Husson B; de Bournonville S; Deiva K; Adamsbaum C; Vincent F; Hocquemiller M; Broissand C; Furlan V; Ballabio A; Fraldi A; Crystal RG; Baugnon T; Roujeau T; Heard JM; Danos O
    Hum Gene Ther; 2014 Jun; 25(6):506-16. PubMed ID: 24524415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death but one unintended consequence of gene-therapy trial.
    Sibbald B
    CMAJ; 2001 May; 164(11):1612. PubMed ID: 11402803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.